HK1198254A1 - Boronate ester compounds and pharmaceutical compositions thereof - Google Patents

Boronate ester compounds and pharmaceutical compositions thereof

Info

Publication number
HK1198254A1
HK1198254A1 HK14111716.4A HK14111716A HK1198254A1 HK 1198254 A1 HK1198254 A1 HK 1198254A1 HK 14111716 A HK14111716 A HK 14111716A HK 1198254 A1 HK1198254 A1 HK 1198254A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
ester compounds
boronate ester
boronate
compounds
Prior art date
Application number
HK14111716.4A
Other languages
English (en)
Chinese (zh)
Inventor
Eric L Elliott
Abu J Ferdous
Michael J Kaufman
Sonja A Komar
Debra L Mazaik
Quentin J Mccubbin
Phoung M Nguyen
Vaithianathan Palaniappan
Raymond D Skwierczynski
Nobel T Truong
Csanad M Varga
Peter N Zawaneh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41061278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1198254(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of HK1198254A1 publication Critical patent/HK1198254A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HK14111716.4A 2008-06-17 2011-11-07 Boronate ester compounds and pharmaceutical compositions thereof HK1198254A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13224408P 2008-06-17 2008-06-17
US21149909P 2009-03-31 2009-03-31

Publications (1)

Publication Number Publication Date
HK1198254A1 true HK1198254A1 (en) 2015-03-20

Family

ID=41061278

Family Applications (9)

Application Number Title Priority Date Filing Date
HK14111508.6A HK1198252A1 (en) 2008-06-17 2011-11-07 Boronate ester compounds and pharmaceutical compositions thereof
HK14111510.2A HK1199260A1 (zh) 2008-06-17 2011-11-07 硼酸酯及其藥劑學成分
HK14111509.5A HK1198253A1 (en) 2008-06-17 2011-11-07 Boronate ester compounds and pharmaceutical compositions thereof
HK11111993.1A HK1157786A1 (en) 2008-06-17 2011-11-07 Boronate ester compounds and pharmaceutical compositions thereof
HK14111716.4A HK1198254A1 (en) 2008-06-17 2011-11-07 Boronate ester compounds and pharmaceutical compositions thereof
HK18104204.4A HK1244811A1 (zh) 2008-06-17 2018-03-27 硼酸酯化合物及其醫藥組合物
HK18104201.7A HK1244809A1 (zh) 2008-06-17 2018-03-27 硼酸酯化合物及其醫藥組合物
HK18104203.5A HK1244810A1 (zh) 2008-06-17 2018-03-27 硼酸酯化合物及其醫藥組合物
HK18104202.6A HK1244827A1 (zh) 2008-06-17 2018-03-27 硼酸酯化合物及其醫藥組合物

Family Applications Before (4)

Application Number Title Priority Date Filing Date
HK14111508.6A HK1198252A1 (en) 2008-06-17 2011-11-07 Boronate ester compounds and pharmaceutical compositions thereof
HK14111510.2A HK1199260A1 (zh) 2008-06-17 2011-11-07 硼酸酯及其藥劑學成分
HK14111509.5A HK1198253A1 (en) 2008-06-17 2011-11-07 Boronate ester compounds and pharmaceutical compositions thereof
HK11111993.1A HK1157786A1 (en) 2008-06-17 2011-11-07 Boronate ester compounds and pharmaceutical compositions thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
HK18104204.4A HK1244811A1 (zh) 2008-06-17 2018-03-27 硼酸酯化合物及其醫藥組合物
HK18104201.7A HK1244809A1 (zh) 2008-06-17 2018-03-27 硼酸酯化合物及其醫藥組合物
HK18104203.5A HK1244810A1 (zh) 2008-06-17 2018-03-27 硼酸酯化合物及其醫藥組合物
HK18104202.6A HK1244827A1 (zh) 2008-06-17 2018-03-27 硼酸酯化合物及其醫藥組合物

Country Status (38)

Country Link
US (17) US20090325903A1 (pt)
EP (6) EP2318419B1 (pt)
JP (9) JP5566380B2 (pt)
KR (5) KR101860743B1 (pt)
CN (10) CN102066386A (pt)
AR (1) AR072162A1 (pt)
AU (1) AU2009260778B2 (pt)
BR (4) BR122014008750A2 (pt)
CA (2) CA2921946C (pt)
CL (1) CL2010001475A1 (pt)
CO (1) CO6321289A2 (pt)
CR (3) CR11850A (pt)
CY (1) CY1116435T1 (pt)
DK (2) DK2730581T3 (pt)
DO (1) DOP2010000384A (pt)
EA (4) EA030685B1 (pt)
EC (2) ECSP11010763A (pt)
ES (2) ES2541467T3 (pt)
GE (2) GEP20135847B (pt)
HK (9) HK1198252A1 (pt)
HR (1) HRP20150592T1 (pt)
IL (3) IL210056B (pt)
MA (1) MA32471B1 (pt)
MX (4) MX349769B (pt)
MY (2) MY155592A (pt)
NO (1) NO2017016I1 (pt)
NZ (4) NZ624121A (pt)
PE (5) PE20141076A1 (pt)
PH (3) PH12015501192B1 (pt)
PL (1) PL2318419T3 (pt)
PT (2) PT2318419E (pt)
RS (1) RS54020B1 (pt)
SG (2) SG10201701524XA (pt)
SI (1) SI2318419T1 (pt)
TW (3) TWI542351B (pt)
UA (1) UA115131C2 (pt)
WO (1) WO2009154737A1 (pt)
ZA (4) ZA201009177B (pt)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237621A (zh) 2005-11-09 2016-01-13 欧尼斯治疗公司 用于酶抑制的化合物
EP2041158B1 (en) 2006-06-19 2013-04-17 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
CL2008002966A1 (es) 2007-10-04 2010-06-25 Onyx Therapeutics Inc Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros.
MX349769B (es) * 2008-06-17 2017-08-11 Millennium Pharm Inc Compuestos de éster boronato y composiciones farmacéuticas de los mismos.
KR101023994B1 (ko) 2008-08-28 2011-03-28 한국생산기술연구원 디지털 밴드용 커넥터, 리셉터클 및 커넥터 조립체
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EA035100B1 (ru) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Комбинированная терапия с применением пептид эпоксикетонов
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
US9359398B2 (en) 2010-03-01 2016-06-07 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
EA029521B1 (ru) * 2010-03-31 2018-04-30 Милленниум Фармасьютикалз, Инк. Производные 1-амино-2-циклопропилэтилбороновой кислоты
US8962572B2 (en) 2010-10-05 2015-02-24 Fresenius Kabi Usa, Llc Bortezomib formulations
CN102784114B (zh) * 2011-05-14 2016-03-02 山东新时代药业有限公司 一种硼替佐米冻干粉针及其制备方法
US20140121182A1 (en) 2011-06-22 2014-05-01 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2776043B1 (en) * 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
JP6286358B2 (ja) 2011-11-11 2018-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
WO2013110005A1 (en) 2012-01-18 2013-07-25 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
EP2810066B1 (en) * 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US20140357596A1 (en) 2012-01-24 2014-12-04 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal cancer
AU2013227219A1 (en) * 2012-03-02 2014-10-23 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
CA2784240C (en) 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
ITMI20121394A1 (it) 2012-08-06 2014-02-07 Chemi Spa Esteri di bortezomib e loro formulazioni
WO2014200969A2 (en) * 2013-06-10 2014-12-18 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
JP6165986B2 (ja) * 2013-08-23 2017-07-19 シントン・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂ．Ｖ． ボルテゾミブを含む医薬組成物
MX2016003979A (es) 2013-10-03 2016-06-15 Millennium Pharm Inc Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.
WO2015117136A1 (en) 2014-02-03 2015-08-06 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
JP2015200016A (ja) * 2014-03-31 2015-11-12 富士フイルム株式会社 水分解用光電極、水分解装置
JP2017524652A (ja) * 2014-05-20 2017-08-31 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤
EP3808349B1 (en) 2014-08-07 2022-10-05 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
WO2016069955A1 (en) * 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
EP3031811A1 (en) 2014-12-09 2016-06-15 Teva Pharmaceuticals Ltd. Malic acid esters of bortezomib
MA41505A (fr) * 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
CZ2015233A3 (cs) 2015-04-03 2016-10-12 Zentiva, K.S. Způsob přípravy Ixazomib citrátu
CZ2015253A3 (cs) 2015-04-15 2016-10-26 Zentiva, K.S. Nové formy Ixazomib citrátu
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
US10144761B2 (en) * 2015-06-19 2018-12-04 Hanlin Scientific Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3120836A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Gebrauchsfertige bortezomib-lösung
EP3120837A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Verfahren zur herstellung einer bortezomibester-lösung
CA2998830A1 (en) * 2015-09-16 2017-03-23 Mylan Laboratories Limited Polymorphs of ixazomib citrate and processes for the preparation thereof
CN106608883A (zh) * 2015-10-21 2017-05-03 北京大学 蛋白酶体抑制剂mln9708的合成方法
EP3370729B1 (en) 2015-11-04 2023-09-27 Takeda Pharmaceutical Company Limited Methods for the identification, evaluation and treatment of patients having multiple myeloma
CN106986884A (zh) * 2016-01-20 2017-07-28 成都贝斯凯瑞生物科技有限公司 一种高效的高纯度含硼化合物制备方法
CN105622658B (zh) * 2016-03-18 2018-06-19 中国药科大学 非肽类蛋白酶体抑制剂、其药物组合物、制备方法和应用
WO2017163190A1 (en) * 2016-03-23 2017-09-28 Dr. Reddy’S Laboratories Limited Amorphous ixazomib citrate and solid dispersion thereof
CN107224569A (zh) * 2016-03-26 2017-10-03 复旦大学 一种硼替佐米水溶性药用组合物及其制备方法和用途
CZ2016204A3 (cs) 2016-04-08 2017-11-01 Zentiva, K.S. Formulace Ixazomib citrátu formy 3
EP3471734B1 (en) * 2016-06-21 2020-11-18 Teva Pharmaceuticals International GmbH Solid state forms of ixazomib citrate
EP3476850A4 (en) 2016-07-25 2019-06-19 Shenzhen Targetrx, Inc. SUBSTITUTED BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION THEREFOR AND APPLICATION THEREOF
WO2018027022A1 (en) * 2016-08-04 2018-02-08 Millennium Pharmaceuticals, Inc. Combination of proteasome inhibitors and anti-cd30 antibodies
CN108440583B (zh) * 2017-01-23 2020-12-04 成都奥璟生物科技有限公司 一种新的硼酸衍生物及其药物组合物
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2018158697A1 (en) 2017-03-03 2018-09-07 Fresenius Kabi Oncology Limited A process for the preparation of ixazomib citrate
WO2018173071A1 (en) * 2017-03-20 2018-09-27 Msn Laboratories Private Limited, R&D Center Novel crystalline forms of ixazomib citrate and its process for preparation thereof
CN106916177B (zh) * 2017-03-23 2019-04-23 南京陵瑞医药科技有限公司 一种氘代的二肽硼酸或其酯类化合物及其合成方法与用途
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
CN108794520B (zh) * 2017-05-02 2020-07-24 北京大学 包括埃沙佐米在内的硼酸柠檬酸酯类化合物的合成方法
WO2019020099A1 (zh) * 2017-07-28 2019-01-31 成都地奥九泓制药厂 一种硼酸酯化合物、其合成方法及其用途
KR20200040295A (ko) 2017-08-24 2020-04-17 메르크 파텐트 게엠베하 보론산 유도체
WO2019038406A1 (en) 2017-08-25 2019-02-28 Synthon B.V. PROCESS FOR THE PREPARATION OF IXAZOMIB OR ITS INTERMEDIATES
CN111065641A (zh) * 2017-09-02 2020-04-24 太阳制药工业有限公司 柠檬酸伊沙佐米的制备方法
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
CN109251218B (zh) * 2017-12-05 2021-08-24 深圳市塔吉瑞生物医药有限公司 一种取代的硼酸酯化合物的制备方法及其晶型
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US10118937B1 (en) 2018-01-03 2018-11-06 Scinopharm Taiwan, Ltd. Process for preparing ixazomib citrate and intermediates therefor
CN110041353A (zh) * 2018-01-16 2019-07-23 成都译山生物科技有限公司 一种新的硼酸水杨酸酯类衍生物及其药物组合物
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN110540547A (zh) * 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途
BR112021001359A2 (pt) 2018-07-26 2021-04-20 Merck Patent Gmbh derivados de ácido borônico
TWI810344B (zh) 2018-08-02 2023-08-01 大陸商正大天晴藥業集團股份有限公司 氮雜環丁烷衍生物的硼酸酯
CN110903310B (zh) * 2018-09-14 2022-11-22 成都奥璟生物科技有限公司 一种硼酸酯类药物及其用途
CN110357787A (zh) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 依沙佐米合成工艺研究
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts
WO2024006337A1 (en) 2022-06-30 2024-01-04 Principia Biopharma Inc. Cyclic boronic esters and their uses

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US449082A (en) * 1891-03-24 milbeadt
US2160413A (en) 1935-04-16 1939-05-30 Schering Ag Polyiodo derivatives of acylamino acids and their salts and a method of making the same
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
JPS6197352A (ja) * 1984-10-17 1986-05-15 Dai Ichi Kogyo Seiyaku Co Ltd 安定性に優れた組成物
JPS6233170A (ja) 1985-08-07 1987-02-13 Tokuyama Soda Co Ltd 環状ポリエ−テル化合物
JPH0813759B2 (ja) 1986-09-01 1996-02-14 富士写真フイルム株式会社 アルコキシベンゼン誘導体の製造方法
JP2512303B2 (ja) 1987-03-20 1996-07-03 呉羽化学工業株式会社 ２−オキサゾリン−４，５−ジオンのフエニルヒドラゾン誘導体
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5159060A (en) * 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
EP0583536B1 (en) * 1992-08-14 1997-03-05 The Procter & Gamble Company Liquid detergents containing an alpha-amino boronic acid
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5935944A (en) * 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US5492900A (en) * 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) * 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
JP3403009B2 (ja) 1996-07-12 2003-05-06 キヤノン株式会社 可動部材の変位と気泡成長を伴う液体吐出方法、該吐出方法に用いられる液体吐出ヘッド、ヘッドカートリッジ及びこれらを用いた液体吐出装置
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
NZ337364A (en) 1997-02-15 2001-06-29 Millennium Pharm Inc Treatment of infarcts, ischemia and reperfusion through inhibition of NFkappaB
WO1999015183A1 (en) 1997-09-25 1999-04-01 Proscript Inc. PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
AU735685B2 (en) 1997-12-16 2001-07-12 Cephalon, Inc. Multicatalytic protease inhibitors for use as anti-tumor agents
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
WO2000024392A1 (fr) 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
US6169076B1 (en) * 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
US6121149A (en) 1999-04-22 2000-09-19 Advanced Micro Devices, Inc. Optimized trench/via profile for damascene filling
KR100307027B1 (ko) 1999-06-17 2001-11-01 서평원 액정 표시장치 및 이것을 이용한 이동 통신 단말기의 표시장치
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
SE0100714D0 (sv) 2000-07-13 2001-02-28 Ap Biotech Ab Reaction vessel and method for distributing fluid in such a vessel
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
JP2002145848A (ja) * 2000-11-10 2002-05-22 Kyorin Pharmaceut Co Ltd アルケニルアミノ酸誘導体及びその製造法
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
AU2002243646B2 (en) 2001-01-25 2006-06-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
PT1399468E (pt) 2001-05-30 2006-05-31 Novartis Ag Derivados do acido 2-{[n-(2-amino-3-(heteroaril ou aril)propionil)-aminoacil]-amino}-alquilboronico
DE10131283A1 (de) 2001-06-28 2003-01-09 Philips Corp Intellectual Pty Phased Array Antenne
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JPWO2003033506A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
US7524883B2 (en) 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
JP2006509034A (ja) 2002-09-09 2006-03-16 トライジェン・リミテッド 選択性トロンビン阻害のための非経口製剤に有用なボロン酸塩
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN1867572B (zh) * 2003-08-14 2012-03-28 赛福伦公司 蛋白酶体抑制剂及其使用方法
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
SG10201600029PA (en) * 2004-03-30 2016-02-26 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
PT2030981E (pt) 2004-05-10 2014-10-14 Onyx Therapeutics Inc Compostos para inibição da enzima proteassoma
WO2006008660A2 (en) 2004-07-20 2006-01-26 Affinium Pharmaceuticals, Inc. Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
CN101120006A (zh) * 2005-02-11 2008-02-06 赛福伦公司 蛋白酶体抑制剂及其使用方法
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
BRPI0609861A2 (pt) 2005-04-29 2010-05-11 Kosan Biosciences Inc uso de 17-aag ou 17-ag ou um pró-fármaco de ambos em combinação com um inibidor de proteassoma na preparação de formulações farmacêuticas para tratar mieloma múltiplo
WO2007005991A1 (en) 2005-07-05 2007-01-11 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
RU2008127486A (ru) * 2005-12-08 2010-01-20 Милленниум Фармасьютикалз, Инк. (Us) Бициклические соединения с ингибиторной активностью в отношении киназы
JP2009524681A (ja) 2006-01-27 2009-07-02 フェノミックス コーポレーション Ｃ型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用
US8022091B2 (en) 2006-02-03 2011-09-20 Taisho Pharmaceutical Co., Ltd. Triazole derivative
CL2007002499A1 (es) * 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009020448A1 (en) 2007-08-06 2009-02-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
ITMI20072397A1 (it) 2007-12-20 2009-06-21 Gambro Lundia Ab Apparecchiatura medicale per il trattamento extracorporeo
MX349769B (es) * 2008-06-17 2017-08-11 Millennium Pharm Inc Compuestos de éster boronato y composiciones farmacéuticas de los mismos.
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EA029521B1 (ru) 2010-03-31 2018-04-30 Милленниум Фармасьютикалз, Инк. Производные 1-амино-2-циклопропилэтилбороновой кислоты
EP2702706B1 (en) 2011-04-29 2014-12-24 Telefonaktiebolaget LM Ericsson (PUBL) Decentralised control of interference reduction in a wireless communication system
JP5724951B2 (ja) 2012-06-11 2015-05-27 日立金属株式会社 ネットワーク管理装置
JP6357023B2 (ja) 2014-06-06 2018-07-11 任天堂株式会社 情報処理プログラム、情報処理装置、情報処理装置の制御方法および情報処理システム

Also Published As

Publication number Publication date
KR101741142B1 (ko) 2017-05-29
SI2318419T1 (sl) 2015-07-31
EA201500432A1 (ru) 2015-11-30
IL210056A0 (en) 2011-02-28
IL234285B (en) 2018-04-30
JP2021165288A (ja) 2021-10-14
ES2541467T3 (es) 2015-07-20
HRP20150592T1 (hr) 2015-07-03
EP2318419B1 (en) 2015-04-08
AR072162A1 (es) 2010-08-11
HK1198253A1 (en) 2015-03-20
HK1157786A1 (en) 2012-07-06
PE20141078A1 (es) 2014-09-05
MY155592A (en) 2015-11-13
JP2014169316A (ja) 2014-09-18
RS54020B1 (en) 2015-10-30
BRPI0915300C1 (pt) 2021-05-25
CA2921946C (en) 2019-01-08
ES2585114T3 (es) 2016-10-03
CA2727862C (en) 2016-04-19
KR101690571B1 (ko) 2016-12-28
EP2733147A1 (en) 2014-05-21
US9175017B2 (en) 2015-11-03
BR122014008753A2 (pt) 2015-12-29
CY1116435T1 (el) 2017-02-08
NO2017016I1 (no) 2017-05-04
DK2318419T3 (en) 2015-06-29
JP2014169317A (ja) 2014-09-18
MY171021A (en) 2019-09-23
JP5566380B2 (ja) 2014-08-06
ZA201009177B (en) 2012-03-28
US9175018B2 (en) 2015-11-03
EP2318419A1 (en) 2011-05-11
US20210198289A1 (en) 2021-07-01
DK2730581T3 (en) 2016-08-15
CR20160014A (es) 2016-02-08
EA201170036A1 (ru) 2011-06-30
ECSP11010763A (es) 2011-02-28
ECSP14010763A (es) 2014-07-31
NZ624123A (en) 2015-11-27
CO6321289A2 (es) 2011-09-20
US20230265111A1 (en) 2023-08-24
CN107253975A (zh) 2017-10-17
TW201002727A (en) 2010-01-16
BR122014008754A2 (pt) 2015-11-03
HK1199260A1 (zh) 2015-06-26
US20220009948A1 (en) 2022-01-13
NZ603236A (en) 2014-05-30
MX358222B (es) 2018-08-10
CA2727862A1 (en) 2009-12-23
DOP2010000384A (es) 2011-01-15
US20180208609A1 (en) 2018-07-26
HK1244810A1 (zh) 2018-08-17
HK1244827A1 (zh) 2018-08-17
CN103450241A (zh) 2013-12-18
EP2730581A1 (en) 2014-05-14
ZA201109368B (en) 2013-10-30
CN103435638A (zh) 2013-12-11
PL2318419T3 (pl) 2015-08-31
TW201433317A (zh) 2014-09-01
US20140018301A9 (en) 2014-01-16
US20190152997A1 (en) 2019-05-23
ZA201504133B (en) 2016-11-30
US20160031913A1 (en) 2016-02-04
JP6110813B2 (ja) 2017-04-05
BRPI0915300B8 (pt) 2020-07-07
EA030685B1 (ru) 2018-09-28
BRPI0915300B1 (pt) 2020-06-23
CN107266482A (zh) 2017-10-20
US20140343314A1 (en) 2014-11-20
KR20140094663A (ko) 2014-07-30
JP2020055829A (ja) 2020-04-09
PH12015501193A1 (en) 2016-01-11
CN107253966A (zh) 2017-10-17
HK1244809A1 (zh) 2018-08-17
PH12015501192A1 (en) 2016-01-11
CN102066386A (zh) 2011-05-18
US20200181176A1 (en) 2020-06-11
EP2730579A1 (en) 2014-05-14
NZ624121A (en) 2015-11-27
US20140349966A1 (en) 2014-11-27
US20180002350A1 (en) 2018-01-04
CN103497210A (zh) 2014-01-08
PE20141064A1 (es) 2014-09-05
US8859504B2 (en) 2014-10-14
GEP201706703B (en) 2017-07-25
EA027346B1 (ru) 2017-07-31
BRPI0915300A2 (pt) 2015-10-27
MX340186B (es) 2016-06-29
JP2014144981A (ja) 2014-08-14
EP2730580A1 (en) 2014-05-14
IL234286A (en) 2017-03-30
TW201433569A (zh) 2014-09-01
PH12015501191B1 (en) 2016-01-11
CN107266480A (zh) 2017-10-20
PT2730581T (pt) 2016-08-17
SG194349A1 (en) 2013-11-29
US20130165390A1 (en) 2013-06-27
JP2017214396A (ja) 2017-12-07
AU2009260778A1 (en) 2009-12-23
JP5926319B2 (ja) 2016-05-25
KR20110043599A (ko) 2011-04-27
KR20170068599A (ko) 2017-06-19
PE20100256A1 (es) 2010-04-14
EP3536693A1 (en) 2019-09-11
AU2009260778B2 (en) 2014-08-28
US11485746B2 (en) 2022-11-01
HK1198252A1 (en) 2015-03-20
PE20141076A1 (es) 2014-09-05
HK1244811A1 (zh) 2018-08-17
JP2023158150A (ja) 2023-10-26
EA201500430A1 (ru) 2015-11-30
PE20141065A1 (es) 2014-09-05
CN103497232A (zh) 2014-01-08
US20090325903A1 (en) 2009-12-31
TWI542351B (zh) 2016-07-21
PT2318419E (pt) 2015-08-25
TWI498333B (zh) 2015-09-01
IL210056B (en) 2018-04-30
US20190048028A1 (en) 2019-02-14
KR101860743B1 (ko) 2018-05-24
NZ624122A (en) 2015-11-27
US20190263839A1 (en) 2019-08-29
US10604538B2 (en) 2020-03-31
CR20160015A (es) 2016-03-09
ZA201304728B (en) 2016-01-27
MA32471B1 (fr) 2011-07-03
KR101704694B1 (ko) 2017-02-08
CA2921946A1 (en) 2009-12-23
CR11850A (es) 2011-03-14
EP2730581B1 (en) 2016-04-27
MX349769B (es) 2017-08-11
CL2010001475A1 (es) 2011-03-11
EA201500431A1 (ru) 2015-11-30
PH12015501192B1 (en) 2016-01-11
JP6010066B2 (ja) 2016-10-19
US20200392164A1 (en) 2020-12-17
US20200247829A1 (en) 2020-08-06
GEP20135847B (en) 2013-06-10
CN103467565A (zh) 2013-12-25
UA115131C2 (uk) 2017-09-25
WO2009154737A1 (en) 2009-12-23
MX2010013642A (es) 2010-12-21
PH12015501191A1 (en) 2016-01-11
KR20140107482A (ko) 2014-09-04
KR20140107483A (ko) 2014-09-04
JP2014196310A (ja) 2014-10-16
KR101691093B1 (ko) 2016-12-29
US20200002361A1 (en) 2020-01-02
JP2011524903A (ja) 2011-09-08
TWI543985B (zh) 2016-08-01
US20150307523A9 (en) 2015-10-29
SG10201701524XA (en) 2017-04-27
BR122014008750A2 (pt) 2015-11-03
US10526351B2 (en) 2020-01-07

Similar Documents

Publication Publication Date Title
HK1244809A1 (zh) 硼酸酯化合物及其醫藥組合物
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0814695D0 (en) Pharmaceutical compositions
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
PT2323623T (pt) Composições farmacêuticas
EP2268278A4 (en) PHARMACEUTICAL COMPOSITION
HK1156844A1 (en) Pharmaceutical composition 271 271
GB0902648D0 (en) Pharmaceutical compounds and compositions
GB0917359D0 (en) Pharmaceutical composition
IL206487A0 (en) Pharmaceutical compositions
GB0908317D0 (en) Pharmaceutical compounds and compositions
GB0817969D0 (en) Pharmaceutical composition
GB0800659D0 (en) Pharmaceutical Compositions
SI2271321T1 (sl) Farmacevtski sestavek 271
GB0903945D0 (en) Pharmaceutical compounds and compositions
GB0902651D0 (en) Pharmaceutical compounds and compositions
GB0919055D0 (en) Pharmaceutical compounds and compositions
GB0908069D0 (en) Pharmaceutical compounds and compositions
GB0806283D0 (en) Pharmaceutical compositions
GB0806156D0 (en) Pharmaceutical compositions
GB0802024D0 (en) Pharmaceutical compositions
EP2308842A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0817566D0 (en) Pharmaceutical composition
GB0817974D0 (en) Pharmaceutical composition